Sg Americas Securities, LLC Acadia Pharmaceuticals Inc Transaction History

Sg Americas Securities, LLC

$27.6 Billion
Q3 2024

A detailed history of Sg Americas Securities, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Sg Americas Securities, LLC holds 517,124 shares of ACAD stock, worth $8.83 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

517,124

Previous 99,476 419.85%

Holding current value

$8.83 Million

Previous $1.62 Million 392.14%

% of portfolio

0.03%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 03, 2024	BUY	$15.14 - $19.14 $6.32 Million - $7.99 Million	417,648 Added 419.85%	517,124 $7.95 Million
Q2 2024 Jul 12, 2024	BUY	$14.62 - $18.42 $212,282 - $267,458	14,520 Added 17.09%	99,476 $1.62 Million
Q1 2024 May 06, 2024	BUY	$17.79 - $30.86 $1.08 Million - $1.87 Million	60,452 Added 246.7%	84,956 $1.57 Million
Q4 2023 Jan 12, 2024	SELL	$20.78 - $31.77 $996,421 - $1.52 Million	-47,951 Reduced 66.18%	24,504 $767,000
Q3 2023 Oct 13, 2023	BUY	$20.84 - $33.47 $1.4 Million - $2.25 Million	67,222 Added 1284.58%	72,455 $1.51 Million
Q2 2023 Jul 10, 2023	SELL	$17.8 - $25.65 $2.61 Million - $3.76 Million	-146,745 Reduced 96.56%	5,233 $125,000
Q1 2023 Apr 28, 2023	BUY	$16.32 - $20.92 $2.25 Million - $2.89 Million	137,924 Added 981.39%	151,978 $2.86 Million
Q4 2022 Feb 02, 2023	SELL	$14.2 - $18.63 $140,452 - $184,269	-9,891 Reduced 41.31%	14,054 $224,000
Q3 2022 Oct 31, 2022	SELL	$14.11 - $18.27 $670,986 - $868,811	-47,554 Reduced 66.51%	23,945 $392,000
Q2 2022 Jul 29, 2022	BUY	$13.01 - $27.22 $845,689 - $1.77 Million	65,003 Added 1000.66%	71,499 $1.01 Million
Q1 2022 Apr 29, 2022	SELL	$20.94 - $27.5 $389,965 - $512,132	-18,623 Reduced 74.14%	6,496 $157,000
Q4 2021 Feb 07, 2022	SELL	$16.79 - $27.09 $613,439 - $989,760	-36,536 Reduced 59.26%	25,119 $586,000
Q3 2021 Nov 01, 2021	BUY	$15.78 - $24.77 $740,823 - $1.16 Million	46,947 Added 319.19%	61,655 $1.02 Million
Q2 2021 Aug 12, 2021	BUY	$19.4 - $27.42 $136,265 - $192,598	7,024 Added 91.41%	14,708 $359,000
Q1 2021 May 13, 2021	BUY	$25.02 - $54.99 $66,202 - $145,503	2,646 Added 52.52%	7,684 $198,000
Q4 2020 Feb 04, 2021	SELL	$41.04 - $56.79 $141,464 - $195,755	-3,447 Reduced 40.62%	5,038 $269,000
Q3 2020 Nov 09, 2020	BUY	$36.42 - $57.0 $11,545 - $18,069	317 Added 3.88%	8,485 $350,000
Q2 2020 Jul 20, 2020	SELL	$39.26 - $52.73 $761,840 - $1.02 Million	-19,405 Reduced 70.38%	8,168 $396,000
Q1 2020 Apr 30, 2020	BUY	$31.65 - $46.87 $195,881 - $290,078	6,189 Added 28.94%	27,573 $1.17 Million
Q4 2019 Jan 28, 2020	SELL	$36.21 - $51.4 $40,663 - $57,722	-1,123 Reduced 4.99%	21,384 $915,000
Q3 2019 Nov 04, 2019	BUY	$22.22 - $44.01 $337,366 - $668,203	15,183 Added 207.3%	22,507 $810,000
Q2 2019 Jul 29, 2019	SELL	$23.32 - $28.12 $75,230 - $90,715	-3,226 Reduced 30.58%	7,324 $196,000
Q1 2019 Apr 29, 2019	SELL	$16.17 - $27.38 $83,615 - $141,581	-5,171 Reduced 32.89%	10,550 $283,000
Q4 2018 Feb 01, 2019	BUY	$14.32 - $22.92 $25,060 - $40,110	1,750 Added 12.53%	15,721 $254,000
Q3 2018 Nov 06, 2018	BUY	$13.03 - $21.81 $58,608 - $98,101	4,498 Added 47.48%	13,971 $290,000
Q2 2018 Aug 07, 2018	SELL	$15.07 - $22.34 $296,969 - $440,232	-19,706 Reduced 67.53%	9,473 $145,000
Q1 2018 May 03, 2018	SELL	$22.47 - $32.33 $780,944 - $1.12 Million	-34,755 Reduced 54.36%	29,179 $656,000
Q4 2017 Jan 24, 2018	BUY	$26.84 - $39.14 $1.6 Million - $2.33 Million	59,588 Added 1371.1%	63,934 $1.93 Million
Q3 2017 Nov 07, 2017	BUY	$29.49 - $38.37 $128,163 - $166,756	4,346	4,346 $164,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Account

Sg Americas Securities, LLC Acadia Pharmaceuticals Inc Transaction History